For the year ending 2025-12-31, TTRX had $4,203,545 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss attributable to common stockholders | -3,194,080 |
| Depreciation and amortization | 52,746 |
| Stock-based compensation expense | 419,245 |
| Non-cash operating lease expense | 1,172 |
| Common stock issued in exchange for services | 250,000 |
| Net gain from change in fair value of derivative liability instrument | 2,574,971 |
| Gain from change in fair value of forward contract liability | -380,442 |
| Amortization of deferred offering cost | 496,948 |
| Prepaid expenses and other current assets | -105,025 |
| Accounts payable and accrued expenses | 2,261,456 |
| Net cash used in operating activities | -2,562,901 |
| Purchases of intangible assets | 152,986 |
| Net cash used in investing activities | -152,986 |
| Proceeds from issuance of stock, net of issuance costs | 6,919,432 |
| Net cash provided by financing activities | 6,919,432 |
| Net increase (decrease) in cash and cash equivalents | 4,203,545 |
| Cash and cash equivalents at beginning of year | 872,599 |
| Cash and cash equivalents at end of year | 5,076,144 |
Turn Therapeutics Inc. (TTRX)
Turn Therapeutics Inc. (TTRX)